The biopharmaceutical manufacturing paradigm is changing rapidly as novel developments take root in analytical testing. From rapid microbial and endotoxin testing to bioassay and quantitative nuclear magnetic resonance spectroscopy (qNMR), the increasing utilization of innovative analytical technologies is spurring a revolution in the biopharmaceutical arena. In the wake of these trends, the analytical testing domain is expected to reach $5.55 billion in the next five years.
This growth is especially driven by the need of biopharmaceutical organizations to maximize throughput and decrease operational expenditure. The organizations are taking full advantage of robust analytical technologies like ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS) for quickly identifying and verifying the chemical structure of biopharmaceutical samples and quantifying it against reference standards. Rapid microbial tests are also gaining traction due to their ability to detect microorganisms in immediate use or short shelf-life therapeutic products before they are administered to patients.
To put the spotlight on such key developments in the industry, Pharma Tech Outlook illustrates how companies are leveraging the latest analytical technologies to augment biopharmaceutical operations and meet the expectations of both physicians delivering medications and patients receiving care. The edition features thought leadership articles from Jennifer L. Riter, Sr. Director of Analytical Services at West Pharmaceutical Services, Inc., Philippe MARC, Executive Director, Global Head of Integrated Data Science at Novartis, and Ming Li, Director, Bioanalytical and Biomarker Outsourcing Operations at Alexion, who shed light on the importance of analytical considerations for combination products, utilization of data science in pharmaceutical R&D, and the acceleration of bioanalytical workflows using automation.
In this edition of Pharma Tech Outlook magazine, we also bring to you the story of some of the top analytical service companies that deliver the best outcomes for their clients. In the list, Valentia Analytical particularly stands out for its cGMP-compliant testing services, which deliver testing data in the shortest time possible to accelerate biopharmaceutical manufacturing. Molecular MS Diagnostics is also a notable mention, known for its contract analytical and bioanalytical research offerings. We also bring you the story of Novotech, an internationally recognized CRO providing clinical development services across all clinical trial phases and therapeutic areas.
Through the following pages, we aim to shine a light on the innovative trends and latest developments in analytical services in the biopharmaceutical industry. We would like to know your thoughts.
